Beta Bionics, Inc. Common Stock (BBNX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $892.71M
Last updated: Nov 17, 2026 at 11:05 AM ET
Beta Bionics, Inc. Common Stock (BBNX) Stock Forecast
Analysts expect Beta Bionics, Inc. Common Stock (BBNX) to earn -$1.83 per share in the fiscal year ending Dec 31, 2026, on revenue of $125.54M. Of 15 analysts, 11 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 73% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 13.3% |
| Buy | 9 | 60.0% |
| Hold | 4 | 26.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 47.1%.
- Fiscal year ending Dec 31, 2026
- -$1.83
- EPS consensus, revenue $125.54M
- Fiscal year ending Dec 31, 2027
- -$2.18
- EPS consensus, revenue $184.65M
- Next report
- Feb 15, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.83 | -$2.00 to -$1.51 | 3 | $125.54M | $123.93M to $127.40M | 14 |
| Dec 31, 2027 | -$2.18 | -$2.76 to -$1.85 | 3 | $184.65M | $170.88M to $194.00M | 14 |
Quarterly Estimates
The EPS consensus falls from -$0.51 for the quarter ending Dec 31, 2026 to -$0.53 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.51 | -$0.62 to -$0.45 | 16 | $31.03M | $28.21M to $33.91M | 16 |
| Mar 31, 2027 | -$0.53 | -$0.62 to -$0.43 | 2 | $35.34M | $33.20M to $38.10M | 10 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.06.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.83 | -$1.88 | -$1.84 | -$1.90 | -$2.06 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.18 | -$2.16 | -$2.33 | -$2.32 | -$2.34 | N/A |
| Quarter ending Mar 31, 2027 | -$0.53 | -$0.53 | -$0.53 | -$0.56 | -$0.57 | N/A |
Frequently Asked Questions About BBNX
What is the BBNX stock forecast?
Consensus analyst estimates put Beta Bionics, Inc. Common Stock's EPS at -$1.83 for the fiscal year ending Dec 31, 2026, on revenue of $125.54M. The consensus rating from 15 analysts is Buy.
How do analysts rate BBNX stock?
Of 15 analysts covering Beta Bionics, Inc. Common Stock, 2 rate it Strong Buy, 9 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from BBNX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.83, with estimates from -$2.00 to -$1.51 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.18, with estimates from -$2.76 to -$1.85 from 3 analysts.
What revenue do analysts expect from Beta Bionics, Inc. Common Stock next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $125.54M, with estimates from $123.93M to $127.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $184.65M, with estimates from $170.88M to $194.00M.
How many analysts cover BBNX?
15 analysts rate Beta Bionics, Inc. Common Stock stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BBNX pages: Overview, Earnings, Forecast, Financials, Competitors